Innova Captab reports 31.1% revenue growth in FY26
Innova Captab Limited reported a 31.1% increase in consolidated revenue to ₹1,630.02 crore for FY26, with PAT rising 9.9% to ₹140.92 crore. The CDMO segment grew 23.8%, while Branded Generics surged 51.4%. The company announced its 22nd AGM on June 29, 2026, via video conferencing, with remote e-voting open from June 26 to June 28.

*this image is generated using AI for illustrative purposes only.
Innova Captab Limited reported a 31.1% increase in consolidated revenue from operations to ₹1,630.02 crore for the financial year ended March 31, 2026, compared to ₹1,243.68 crore in the previous year. Profit After Tax (PAT) rose 9.9% to ₹140.92 crore. The company has convened its 22nd Annual General Meeting on June 29, 2026, via video conferencing to adopt the audited financial statements and consider director re-appointments. Additionally, the company communicated the specific web link for accessing the Annual Report 2025-26 to shareholders in compliance with SEBI LODR amendments.
Key AGM Details
The 22nd AGM will be held on Monday, June 29, 2026, at 11:30 AM IST. The record date for determining shareholder eligibility is June 22, 2026. Remote e-voting is available from June 26, 2026, at 09:00 AM IST until June 28, 2026, at 05:00 PM IST. The agenda includes the re-appointment of M/s. B S R & Co. LLP as Statutory Auditors for a five-year term and the ratification of Cost Auditor remuneration. Ms. Sandhya R Malhotra, Partner of M/s. Manish Ghia & Associates, has been appointed as the Scrutinizer for the e-voting process.
| Event | Date | Time |
|---|---|---|
| AGM Date | June 29, 2026 | 11:30 AM IST |
| Record Date | June 22, 2026 | — |
| E-Voting Start | June 26, 2026 | 09:00 AM IST |
| E-Voting End | June 28, 2026 | 05:00 PM IST |
FY2025-26 Financial Performance
The company delivered strong consolidated results, with EBITDA growing 26.3% to ₹250.34 crore. On a standalone basis, revenue increased 35.6% to ₹12,988.14 million, while standalone profit declined 6.46% to ₹836.92 million due to fixed costs at the Kathua facility. The board declared an interim dividend of ₹2 per share during the year.
| Metric | FY2025-26 | FY2024-25 | Change (%) |
|---|---|---|---|
| Revenue from Operations | ₹1,630.02 crore | ₹1,243.68 crore | +31.1% |
| EBITDA | ₹250.34 crore | ₹198.20 crore | +26.3% |
| EBITDA Margin | ~15.4% | ~15.9% | — |
| Profit After Tax (PAT) | ₹140.92 crore | ₹128.26 crore | +9.9% |
Business Segment Performance
Innova Captab restructured operations into CDMO Services & Products and Branded Generics. The CDMO segment contributed 70% of total revenue, growing 23.8% to ₹1,133.35 crore. The Branded Generics segment surged 51.4% to ₹496.67 crore. Exports accounted for 31.3% of total revenue, with the company serving over 350 clients across 60+ countries.
| Segment | FY2025-26 | FY2024-25 | YoY Growth |
|---|---|---|---|
| CDMO Revenue | ₹1,133.35 crore | ₹915.62 crore | +23.8% |
| Branded Generics Revenue | ₹496.67 crore | ₹328.06 crore | +51.4% |
Operational Highlights
The greenfield facility at Kathua, Jammu commenced operations in January 2025 and achieved full-year operations in FY2026, receiving WHO-GMP and PIC/S certifications. The Baddi facility secured UK-MHRA GMP compliance certification. R&D investment increased to ₹7.00 crore from ₹6.55 crore in the previous year. The company's market capitalisation stood at ₹3,948 crore as on March 31, 2026.
Historical Stock Returns for Innova Captab
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.61% | +6.57% | +16.27% | +39.06% | +14.74% | +83.64% |
How will the recent WHO-GMP and PIC/S certifications at the Kathua facility impact the company's ability to secure new international CDMO contracts?
What strategies will management employ to bridge the margin gap, given that EBITDA growth lagged behind revenue expansion?
With Branded Generics growing over 50%, will the company look to rebalance its revenue mix away from the current 70% reliance on CDMO services?































